XNAS
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Apnimed’s quarter looks excellent on the surface, but the real story is the **$3.91 EPS beat** versus a $0.34 loss estimate, driven by a still-early **$12M revenue** base. As a development-stage biotech, results are more about capital formation than commercial momentum, so the headline beat is not yet durable.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | Q2 2026 | -0.34 | 3.92 | +1252.94% | $12.1M | ✅ Beat | +0.69% | -11.22% | — |
Showing last 1 quarters.